BACKGROUND: Blood pressure screening is an important component of cardiovascular disease prevention, but a hypertension diagnosis (i.e., label) can have unintended negative effects on patients' well-being. Despite persistent disparities in hypertension prevalence and outcomes, whether the impact of labeling differs by race is unknown. The purpose of this study was to evaluate possible race differences in the relationship between hypertension labeling and health-related quality of life and depression. METHODS: The sample included 308 normotensive and unmedicated hypertensive subjects from the Neighborhood Study of Blood Pressure and Sleep, a cross-sectional study conducted between 1999 and 2003. Labeled hypertension was defined (by self-report) as having been diagnosed with high blood pressure or prescribed antihypertensive medications. Effects of labeling and race on self-reported physical and mental health and depressive symptoms were tested using multivariate analysis of covariance, controlling for age, sex, body mass index (BMI), previous medication use, and "true" hypertension status, defined by average daytime ambulatory blood pressure (ABP). RESULTS: Both black and white subjects who had been labeled as hypertensive reported similarly poorer physical health than unlabeled subjects (P = 0.001). However, labeling was associated with poorer mental health and greater depressive symptoms only among blacks (Ps < 0.05 for the interactions). These findings were not explained by differences in socioeconomic status. CONCLUSIONS: These results are consistent with previous studies showing negative effects of hypertension labeling, and demonstrate important race differences in these effects. Clinical approaches to communicating diagnostic information that avoid negative effects on well-being are needed, and may require tailoring to patient characteristics such as race.
BACKGROUND: Blood pressure screening is an important component of cardiovascular disease prevention, but a hypertension diagnosis (i.e., label) can have unintended negative effects on patients' well-being. Despite persistent disparities in hypertension prevalence and outcomes, whether the impact of labeling differs by race is unknown. The purpose of this study was to evaluate possible race differences in the relationship between hypertension labeling and health-related quality of life and depression. METHODS: The sample included 308 normotensive and unmedicated hypertensive subjects from the Neighborhood Study of Blood Pressure and Sleep, a cross-sectional study conducted between 1999 and 2003. Labeled hypertension was defined (by self-report) as having been diagnosed with high blood pressure or prescribed antihypertensive medications. Effects of labeling and race on self-reported physical and mental health and depressive symptoms were tested using multivariate analysis of covariance, controlling for age, sex, body mass index (BMI), previous medication use, and "true" hypertension status, defined by average daytime ambulatory blood pressure (ABP). RESULTS: Both black and white subjects who had been labeled as hypertensive reported similarly poorer physical health than unlabeled subjects (P = 0.001). However, labeling was associated with poorer mental health and greater depressive symptoms only among blacks (Ps < 0.05 for the interactions). These findings were not explained by differences in socioeconomic status. CONCLUSIONS: These results are consistent with previous studies showing negative effects of hypertension labeling, and demonstrate important race differences in these effects. Clinical approaches to communicating diagnostic information that avoid negative effects on well-being are needed, and may require tailoring to patient characteristics such as race.
Authors: Thomas G Pickering; John E Hall; Lawrence J Appel; Bonita E Falkner; John Graves; Martha N Hill; Daniel W Jones; Theodore Kurtz; Sheldon G Sheps; Edward J Roccella Journal: Hypertension Date: 2004-12-20 Impact factor: 10.190
Authors: Francisco J Mena-Martin; Juan C Martin-Escudero; Fernando Simal-Blanco; Jose L Carretero-Ares; Delfin Arzua-Mouronte; Vicente Herreros-Fernandez Journal: J Hypertens Date: 2003-07 Impact factor: 4.844
Authors: Nancy R Kressin; Fei Wang; Judith Long; Barbara G Bokhour; Michelle B Orner; James Rothendler; Christine Clark; Surekha Reddy; Waldemar Kozak; Laura P Kroupa; Dan R Berlowitz Journal: J Gen Intern Med Date: 2007-03-16 Impact factor: 5.128
Authors: Andrew Camp; Sarah R Wellik; Jonathan H Tzu; William Feuer; Kristopher L Arheart; Ananth Sastry; Anat Galor Journal: Cont Lens Anterior Eye Date: 2015-02-24 Impact factor: 3.077
Authors: Tanya M Spruill; Seth D Feltheimer; Manjunath Harlapur; Joseph E Schwartz; Gbenga Ogedegbe; Youngjun Park; William Gerin Journal: J Psychosom Res Date: 2013-02-15 Impact factor: 3.006
Authors: Cassandra D Ford; Patricia Sawyer; Patricia Parmelee; Olivio J Clay; Martha Crowther; Richard M Allman Journal: J Health Dispar Res Pract Date: 2014
Authors: Ian M Kronish; Donald Edmondson; Daichi Shimbo; Jonathan A Shaffer; Lawrence R Krakoff; Joseph E Schwartz Journal: Am J Hypertens Date: 2018-06-11 Impact factor: 2.689
Authors: Paul Muntner; Cora E Lewis; Keith M Diaz; April P Carson; Yongin Kim; David Calhoun; Yuichiro Yano; Anthony J Viera; Daichi Shimbo Journal: Am J Hypertens Date: 2014-11-04 Impact factor: 3.080